Rezolute

Rezolute is a late-stage rare disease company dedicated to significantly improving treatment outcomes for patients with hypoglycemia caused by hyperinsulinism (HI). The company's antibody therapy, RZ358, is specifically designed to treat various forms of hyperinsulinism and has demonstrated remarkable efficacy in clinical trials and real-world applications for congenital hyperinsulinism and tumor-induced hyperinsulinism.